Weight Management Protocol
LiraglutideComplete Dosing & Administration Guide
FDA-approved once-daily GLP-1 receptor agonist (Victoza/Saxenda) that reduces HbA1c by 0.9–1.6%, promotes 5–10% body weight loss, and demonstrated a 13% reduction in major adverse cardiovascular events in the landmark LEADER trial of 9,340 patients
Dose Range
0.6-3.0mg
Frequency
Once daily
Route
Subcutaneous injection
Cycle Length
Ongoing/indefinite
Dosing
How much
do I take?
Starting Dose
0.6 mg subcutaneous once daily
Begin at 0.6 mg daily for the first week to assess gastrointestinal tolerability before dose escalation. This starting dose is sub-therapeutic for both diabetes and obesity indications. Inject in abdomen, thigh, or upper arm at any time of day regardless of meals. Rotate injection sites. GI side effects (nausea) are most common during the initial titration period.
Standard Dose
1.2–1.8 mg subcutaneous once daily
Standard therapeutic dose range for type 2 diabetes (Victoza). Escalate from 0.6 mg to 1.2 mg at week 2 and optionally to 1.8 mg at week 3 for additional glycemic benefit. Maximum diabetes dose is 1.8 mg/day. No dose adjustment needed for renal or hepatic impairment. If combining with sulfonylureas, reduce sulfonylurea dose by 50% to minimize hypoglycemia. Store in-use pen at room temperature or refrigerated for up to 30 days.
Advanced Dose
3.0 mg subcutaneous once daily
Obesity dose (Saxenda) reached through weekly 0.6 mg increments: 0.6→1.2→1.8→2.4→3.0 mg over 5 weeks. Evaluate response at 16 weeks — if <4% body weight loss, consider discontinuation as unlikely to achieve meaningful benefit. Must be combined with reduced-calorie diet and increased physical activity. Approved for BMI ≥30 or BMI ≥27 with weight-related comorbidities. Do not use simultaneously with Victoza or any other GLP-1 RA.
Timing
Best time to take
Administer Liraglutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Liraglutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Liraglutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Administration
How do I
use it?
Reconstitution
What you need
- •Liraglutide vial (lyophilized powder or solution)
- •Bacteriostatic water or sterile sodium chloride for reconstitution
- •Alcohol swabs for cleaning vial tops and injection sites
- •Appropriately sized syringes with fine-gauge needles (27-30 gauge)
- •Sharps disposal container
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- •Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- •Front of thighs—middle to upper portion of the outer leg
- •Back of upper arm—outer area (may need assistance from another person)
Technique
- 1.Wash your hands thoroughly with soap and water before handling supplies
- 2.Clean the injection site with an alcohol swab and let it air dry completely
- 3.Pinch a fold of skin at the chosen injection site
- 4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 5.Inject the medication slowly and steadily over 5-10 seconds
- 6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 7.Rotate injection sites to prevent tissue irritation or lipodystrophy
- 8.Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Liraglutide (Victoza, Saxenda) is FDA-approved with extensive safety data from 15+ years of clinical use in diabetes (GLP-1 agonist) and obesity indications. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of patients during dose escalation but diminish significantly after 2-3 weeks of stable dosing. Black box warnings include risk of medullary thyroid carcinoma and pancreatitis, though absolute incidence remains rare. Injection site reactions are minimal. The compound shows no hepatotoxicity, nephrotoxicity, or major drug interactions at approved doses.
Liraglutide safety derives from LEAD Phase 3 diabetes trials (2008-2009) enrolling thousands of patients, SCALE obesity trials (2013-2014), and decades of post-marketing surveillance. Published in New England Journal of Medicine and Diabetes Care, these studies establish favorable cardiovascular outcomes and weight reduction with well-characterized adverse event profiles. Regulatory oversight by FDA and EMA continues monitoring thyroid-related safety signals.
Common Side Effects
Experienced by some users
Nausea
Most frequent adverse effect (20–40% incidence), typically dose-dependent and most pronounced during the first weeks of therapy and dose escalation. Generally mild to moderate and transient.
Management: Gradual dose titration per prescribing schedule. Eat smaller, more frequent meals. Avoid high-fat or very large meals. Most patients develop tolerance within 4–8 weeks.
Diarrhea
Occurs in 15–20% of patients, usually mild to moderate in severity. Related to GLP-1 receptor-mediated effects on gastrointestinal motility.
Management: Stay well hydrated. Dietary adjustments (BRAT diet if needed). Usually self-limiting within the first few weeks of therapy.
Vomiting
Reported in 9–15% of patients, typically during dose escalation. Dose-dependent and generally decreases with continued therapy.
Management: Slow dose titration. Temporarily hold at current dose if vomiting is persistent. Anti-emetics may be used short-term if needed.
Decreased appetite and headache
Reduced appetite (therapeutic effect for weight management) and headache (5–10%) are common during initiation. Constipation (10–15%) may also occur.
Management: Appetite reduction is expected and therapeutic. Headache typically resolves with hydration and time. Constipation managed with adequate fiber and fluid intake.
Less Common
- •Injection site reactions
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Liraglutide
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Liraglutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Other GLP-1 receptor agonists (semaglutide, exenatide, dulaglutide) — redundant mechanism with increased adverse effects and no additional benefit - Use with caution—discuss with your healthcare provider.
- !DPP-4 inhibitors (sitagliptin, saxagliptin) — overlapping incretin pathway mechanism; inferior to liraglutide monotherapy in head-to-head trials - Use with caution—discuss with your healthcare provider.
- !Sulfonylureas at full dose — increased hypoglycemia risk requires 50% sulfonylurea dose reduction when adding liraglutide - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Liraglutide. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Want the Full Picture?
View the complete Liraglutide research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.
View Full Liraglutide Profile